Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

OMER – Omeros Corporation

Float Short %

19.58

Margin Of Safety %

Put/Call OI Ratio

0.5

EPS Next Q Diff

EPS Last/This Y

1.45

EPS This/Next Y

1.29

Price

9.2

Target Price

33.67

Analyst Recom

1.8

Performance Q

128.29

Relative Volume

0.54

Beta

2.46

Ticker: OMER



19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-17OMER9.080.510.13110023
2025-11-18OMER8.480.520.42110047
2025-11-19OMER8.20.520.21126992
2025-11-20OMER8.220.510.19129811
2025-11-21OMER8.880.500.06134808
2025-11-24OMER9.770.440.2099581
2025-11-25OMER9.450.440.05102956
2025-11-26OMER9.640.440.57103272
2025-12-01OMER9.680.451.00103994
2025-12-02OMER9.420.470.46106101
2025-12-03OMER10.630.470.22107002
2025-12-04OMER11.020.470.30107648
2025-12-05OMER10.850.480.39107436
2025-12-08OMER11.40.480.17108526
2025-12-09OMER11.450.480.11109733
2025-12-10OMER11.240.480.80112204
2025-12-11OMER10.550.500.48116893
2025-12-12OMER10.170.510.12119449
2025-12-15OMER9.210.500.48120446
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1



19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-17OMER9.097.7- -2.02
2025-11-18OMER8.487.7- -1.25
2025-11-19OMER8.227.7- -1.25
2025-11-20OMER8.237.7- -1.25
2025-11-21OMER8.87129.6- -1.25
2025-11-24OMER9.77129.6- -1.25
2025-11-25OMER9.45129.6- -1.25
2025-11-26OMER9.63129.6- -1.25
2025-12-01OMER9.68129.6- -1.25
2025-12-02OMER9.43129.6- -1.25
2025-12-03OMER10.62129.6- -1.25
2025-12-04OMER11.02129.6- -1.25
2025-12-05OMER10.85129.6- -1.25
2025-12-08OMER11.40129.6- -1.25
2025-12-09OMER11.47129.6- -1.25
2025-12-10OMER11.25129.6- -1.25
2025-12-11OMER10.58129.6- -1.25
2025-12-12OMER10.15129.6- -1.25
2025-12-15OMER9.20129.6- -1.25
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1



19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-17OMER0.006.260
2025-11-18OMER0.006.2617.85
2025-11-19OMER0.006.2617.85
2025-11-20OMER0.006.2617.85
2025-11-21OMER0.006.2617.85
2025-11-24OMER0.006.1817.85
2025-11-25OMER0.006.1817.85
2025-11-26OMER0.006.1819.61
2025-12-01OMER0.006.1719.61
2025-12-02OMER0.006.1719.61
2025-12-03OMER0.006.1719.61
2025-12-04OMER0.006.1719.61
2025-12-05OMER0.006.1719.61
2025-12-08OMER0.006.1819.61
2025-12-09OMER0.006.1819.61
2025-12-10OMER0.006.1819.61
2025-12-11OMER0.006.1819.61
2025-12-12OMER0.006.1819.61
2025-12-15OMER0.006.1819.58
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

[stock_market_widget type="chart" template="candlestick" assets="OMER" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]

Last Quarter Act. EPS​

-0.19

Avg. EPS Est. Current Quarter

0.16

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

6.18

Beta

2.46

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

27

Growth Score

20

Sentiment Score

8

Actual DrawDown %

61.4

Max Drawdown 5-Year %

-95.4

Target Price

33.67

P/E

Forward P/E

216.47

PEG

P/S

P/B

P/Free Cash Flow

EPS

-2.02

Average EPS Est. Cur. Y​

-1.25

EPS Next Y. (Est.)

0.04

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.54

Return on Equity vs Sector %

28

Return on Equity vs Industry %

43

EPS 1 7Days Diff

EPS 1 30Days Diff

0.76

EBIT Estimation

[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”OMER” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”OMER” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”OMER” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”OMER” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”OMER” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”OMER” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”OMER” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
Omeros Corporation
Sector: Healthcare
Industry: Biotechnology
Employees: 202
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
stock quote shares OMER – Omeros Corporation Stock Price stock today
news today OMER – Omeros Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch OMER – Omeros Corporation yahoo finance google finance
stock history OMER – Omeros Corporation invest stock market
stock prices OMER premarket after hours
ticker OMER fair value insiders trading